The Pharmaceutical Society of Japan, established in 1880, is one of Japan’s oldest and most distinguished academic societies. The Society currently has around 18,000 members. It publishes three monthly scientific journals. Chemical and Pharmaceutical Bulletin (Chem. Pharm. Bull.) began publication in 1953 as Pharmaceutical Bulletin. It covers chemistry fields in the pharmaceutical and health sciences. Biological and Pharmaceutical Bulletin (Biol. Pharm. Bull.) began publication in 1978 as the Journal of Pharmacobio-Dynamics. It covers various biological topics in the pharmaceutical and health sciences. A fourth Society journal, the Journal of Health Science, was merged with Biol. Pharm. Bull. in 2012. Yakugaku Zasshi (Japanese for “Pharmaceutical Science Journal”) has the longest history, with publication beginning in 1881. Yakugaku Zasshi is published mostly in Japanese, except for some articles related to clinical pharmacy and pharmaceutical education, which are published in English.
The main aim of the Society’s journals is to advance the pharmaceutical sciences with research reports, information exchange, and high-quality discussion. The average review time for articles submitted to the journals is around one month for first decision. The complete texts of all of the Society’s journals can be freely accessed through J-STAGE. The Society’s editorial committee hopes that the content of its journals will be useful to your research, and also invites you to submit your own work to the journals.

Chairman of Committee
Ken-ichi Hosoya
Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama 
Read more
Published by The Pharmaceutical Society of Japan  
16,832 registered articles
(updated on May 26, 2018)
Online ISSN : 1347-5231
Print ISSN : 0031-6903
Featured article
Volume 138 (2018) Issue 5 Pages 591-598
Development of a Novel Liposomal DDS by Manipulating Pharmacokinetics and Intracellular Trafficking for Drug Therapy and Nucleic Acid Medicine Read more
Editor’s picks

 The modification of polyethylene glycol (PEG), i.e. PEGylation is commonly used approach for increasing stability of drug delivery systems (DDSs), but results in loss of activity simultaneously. This article describes the trade-off relationship between activity and stability as PEG dilemma and strategies to overcome PEG dilemma. The authors developed a cleavable PEG lipid in response to tumor microenvironment, a pH-sensitive fusogenic peptide, and pH-sensitive cationic lipids in response to endosome/lysosome, which balanced activity and stability of DDSs and exerted therapeutic effect of nucleic acid cargos.

View the past featured articles
View all articles in Current issue
Most viewed articles Apr.2018
Share this page
Select past volume & issue